| Issue | Title | |
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract PDF (Rus) |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| Vol 10, No 4 (2017) | THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE | Abstract PDF (Rus) |
| Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva | ||
| Vol 10, No 3 (2017) | The strategies of drug supply for patients with chronic hepatitis C | Abstract PDF (Rus) |
| E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin | ||
| Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract PDF (Rus) |
| V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract PDF (Rus) |
| N. Z. Musina, V. K. Fedyaeva | ||
| Vol 12, No 1 (2019) | The use of the level of evidence and grade of recommendations scales in developing clinical guidelines in the Russian Federation | Abstract PDF (Rus) |
| N. I. Zhuravleva, L. C. Shubina, O. A. Sukhorukikh | ||
| Vol 13, No 3 (2020) | The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups | Abstract PDF (Rus) |
| E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan | ||
| Vol 11, No 4 (2018) | Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions | Abstract PDF (Rus) |
| G. R. Hachatryan, T. S. Teptsova, V. A. Lemeshko, N. Z. Musina | ||
| Vol 18, No 1 (2025) | Trends in the industry of clinical trials | Abstract PDF (Rus) |
| S. S. Milovanov, V. V. Popov, N. V. Teplova | ||
| Vol 5, No 1 (2012) | UN MILLENNIUM DEVELOPMENT GOALS INDICATORS ON PROBLEMS OF ACCESS TO ESSENTIAL MEDICINES AND ENHANCEMENT OF LOCAL PHARMACEUTICAL PRODUCER IN DEVELOPING COUNTRIES | Abstract |
| A. Y. Kulikov, A. G. Voskanyan | ||
| Vol 15, No 4 (2022) | Unified system and classification of indicators for integral assessment of the performance and effectiveness of medical care organization at the regional level in the Russian Federation | Abstract PDF (Rus) |
| V. V. Omelyanovskiy, I. А. Mikhailov, D. V. Lukyantseva, Е. S. Samsonova, G. G. Lebedenko | ||
| Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract PDF (Rus) |
| D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract PDF (Rus) |
| S. K. Zyryanov, I. N. Dyakov | ||
| Vol 11, No 3 (2018) | Use of medications in children hospitalized with community-acquired pneumonia | Abstract PDF (Rus) |
| D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova | ||
| Vol 6, No 4 (2013) | Using indirect comparisons in pharmacoeconomic examination | Abstract PDF (Rus) |
| Yu. E. Balykina, A. S. Kolbin | ||
| Vol 5, No 1 (2012) | VI CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» | Abstract PDF (Rus) |
| Vol 5, No 2 (2012) | VI Конгресс с международным участием «Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации» | Abstract PDF (Rus) |
| Vol 6, No 1 (2013) | VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» | Abstract PDF (Rus) |
| Vol 6, No 2 (2013) | VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» | Abstract PDF (Rus) |
| Vol 11, No 3 (2018) | What is the role of antineoplastic drug safety in reimbursement decision making? | Abstract PDF (Rus) |
| A. S. Kolbin, A. A. Kurylev | ||
| Vol 5, No 2 (2012) | WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM | Abstract PDF (Rus) |
| A. I. Borodin | ||
| Vol 5, No 3 (2012) | а | Abstract PDF (Rus) |
| а а | ||
| Vol 5, No 3 (2012) | а | Abstract PDF (Rus) PDF (Eng) |
| а а | ||
| Vol 7, No 4 (2014) | АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS | Abstract PDF (Rus) |
| P. S. Nosova, O. V. Reshetko | ||
| Vol 9, No 2 (2016) | Гендерные особенности в отношениях населения к лекарственным средствам | Abstract |
| Vol 18, No 3 (2025) | Еffect of standardized omega-3 polyunsaturated fatty acids on indicators of multiple organ pathology in an experimental aging model | Abstract PDF (Rus) |
| O. A. Gromova, A. A. Garanin, I. Yu. Torshin, V. I. Demidov, T. E. Bogacheva | ||
| Vol 9, No 3 (2016) | МЕТОД «ЗАТРАТЫ – ЭФФЕКТИВНОСТЬ» В ОЦЕНКЕ АНТИБИОТИКОТЕРАПИИ ОСТРОГО ОБСТРУКТИВНОГО БРОНХИТА У ДЕТЕЙ В УСЛОВИЯХ СТАЦИОНАРА | Abstract |
| , | ||
| Vol 9, No 3 (2016) | Мониторинг потребительского отношения населения к лекарственным средствам | Abstract |
| Vol 10, No 2 (2017) | Особенности клинико-экономической оценки терапии хронических заболеваний: несоответствие результатов классического фармакоэкономического и социально-экономического анализов | Abstract |
| , | ||
| Vol 10, No 3 (2017) | оценка экономического ущерба от рассеянного склероза в г. Уфа. | Abstract |
| , | ||
| Vol 12, No 3 (2019) | Пост-релиз Международной научно-практической конференции на тему: «Развитие оценки технологий здравоохранения в странах СНГ» | Abstract PDF (Rus) |
| article Editorial | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract PDF (Rus) |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| Vol 9, No 2 (2016) | Управленческий аспект проблемы использования наркотических лекарственных средств | Abstract |
| , , | ||
| Vol 10, No 2 (2017) | ФАРМАКОЭКОНОМИЧЕСКАЯ ОЦЕНКА ПРИМЕНЕНИЯ ПОМАЛИДОМИДА (ИМНОВИД) ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С РЕЦИДИВИРУЮЩЕЙ И РЕФРАКТЕРНОЙ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ | Abstract |
| , | ||
| Vol 10, No 2 (2017) | Фармакоэкономический анализ стоимости антиретровирусных препаратов, применяемых в терапии ВИЧ-инфицированных пациентов. | Abstract |
| , | ||
| Vol 10, No 2 (2017) | Фармакоэкономический анализ стоимости антиретровирусных препаратов, применяемых в терапии ВИЧ-инфицированных пациентов. | Abstract |
| , | ||
| Vol 9, No 4 (2016) | ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ КОМБИНАЦИИ ОЛМЕСАРТАН/ЛЕРКАНИДИПИН И ЗОФЕНОПРИЛ/ЛЕРКАНИДИПИН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ | Abstract |
| Vol 9, No 2 (2016) | Фармакоэкономический анализ терапии пациентов с ХОБЛ в стационарных условиях. | Abstract |
| Vol 9, No 3 (2016) | Эффективность и безопасность пероральных антикоагулянтов при венозных тромбоэмболических осложнениях: непрямые сравнения | Abstract |
| 501 - 539 of 539 Items | << < 6 7 8 9 10 11 | |
Browse Title Index
Popular articles
Vol 10, No 1 (2017)
Vol 17, No 3 (2024)
Vol 16, No 3 (2023)
Vol 16, No 4 (2023)
Vol 13, No 1 (2020)
Vol 14, No 4 (2021)
Keywords
COVID-19
artificial intelligence
budget impact analysis
chemotherapy
children
chondroitin sulfate
clinical and economic analysis
cost minimization analysis
cost-effectiveness analysis
cost-utility analysis
drug supply
drugs
glucosamine sulfate
health technology assessment
oncology
pharmaceutical market
pharmacoeconomic analysis
pharmacoeconomics
pharmacoepidemiology
pharmacoinformatics
quality of life
Publisher: IRBIS LLC
24 Chechersky St., Moscow 117042
Phone: +7 (495) 649 54 95
Email: digevskaya@irbis-1.ru
